Latest news about Nephrocare Health Services
Nephrocare Health Services
598.70
-6.40(-1.06%)
Company Performance:
View Company Insights1D-1.06%
1M+11.15%
6M+27.05%
1Y+27.05%
5Y+27.05%
More news about Nephrocare Health Services
27May 26
Nephrocare Health Services to attend investor meet on June 18-19
Nephrocare Health Services Limited announced its participation in the HSBC Singapore Conference on June 18-19, 2026, in Mumbai. Officials will hold group and one-on-one meetings with analysts and investors based on publicly available information. The company confirmed that no unpublished price sensitive information will be discussed during these sessions.
27May 26
Nephrocare incorporates Kazakhstan subsidiary to expand dialysis network
Nephrocare Health Services incorporated a step-down subsidiary, NEPHROPLUS HEALTH SERVICES KAZAKHSTAN LLP, on May 26, 2026, to expand its dialysis network. The entity has a charter capital of KZT 5,000,000 and is wholly controlled indirectly through Nephrocare Health Services International Pte. Ltd.
23May 26
Nephrocare to attend investor meet on June 2
Nephrocare Health Services announced its participation in an investor conference on June 2, 2026, organized by Axis Capital in Mumbai. The meeting will involve group and one-on-one discussions based on publicly available information, with no UPSI to be shared.
20May 26
Nephrocare FY26 net loss at ₹80.60 million
Nephrocare Health Services Limited reported a standalone net loss of ₹80.60 million for the financial year ended March 31, 2026, against a net profit of ₹342.36 million in the previous year, while consolidated net profit increased to ₹768.40 million. Revenue from operations grew to ₹6,297.43 million on a standalone basis and ₹9,988.45 million on a consolidated basis. The board approved further investments in overseas subsidiaries and re-appointed M/s. BDO India LLP as Internal Auditor.
19May 26
Nephrocare Health Services Announces Investment of Up to 100 Million Rupees in Nepal Subsidiary
Nephrocare Health Services has announced an investment of up to 100 million rupees in Nephrocare Health Services Nepal. The announcement highlights the company's cross-border capital allocation toward its Nepal-based entity. No additional financial metrics or timelines were disclosed alongside this announcement.
13May 26
Nephrocare Unit Acquires Philippines Dialysis Center Assets for PHP 89.6 Million
Nephrocare Health Services Limited disclosed that its step-down wholly-owned subsidiary, Nephrocare Health Care Services, Philippines Inc., has acquired dialysis center assets in Orani, Bataan, Philippines for PHP 89,600,000.00 through an Asset Transfer Agreement dated May 12, 2026, with Orani Hemodialysis Center Inc. The transaction, made under Regulation 30 of SEBI LODR, involves no special rights and is not classified as a related party transaction.
05May 26
Nephrocare Health Services Schedules Q4FY26 Earnings Conference Call for May 20, 2026
Nephrocare Health Services has scheduled its Q4FY26 Results Conference Call for May 20, 2026, at 16:00 IST, hosted by ICICI Securities. Senior leadership including the CMD, Co-Founder, Group CEO, and Group CFO will represent the company. The call will cover audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, with discussions limited to publicly available information.
04May 26
Nephrocare Health Services Schedules Board Meeting on May 19, 2026 to Approve Q4 and FY26 Financial Results
Nephrocare Health Services Limited has informed stock exchanges of a Board of Directors meeting scheduled for May 19, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The intimation was issued on May 04, 2026, under reference NEPHROPLUS/SE/030. The trading window for designated persons and their immediate relatives has been closed from April 01, 2026 till May 21, 2026 (both days inclusive), in line with applicable SEBI regulations.
03Apr 26
Nephrocare Health Services Designates CFO Prashant Goenka as Chief Risk Officer
Nephrocare Health Services Limited has designated Mr. Prashant Vinodkumar Goenka as Chief Risk Officer effective April 03, 2026, in addition to his existing CFO role. The Board of Directors approved the appointment through circular resolution on the same date. Mr. Goenka brings over 20 years of financial services expertise from leading institutions including HSBC, Bank of America, and JP Morgan Chase, with experience across USA, Philippines, and India.
02Apr 26
Nephrocare Health Services Files Writ Petition Challenging ₹2.51 Crore GST Demand
Nephrocare Health Services Limited filed a writ petition on April 02, 2026 challenging GST orders worth ₹2.51 crore before the Hon'ble High Court of Jammu & Kashmir and Ladakh at Srinagar. The dispute involves alleged turnover mismatch between Form 26AS and GST returns for FY 2020-21, with demands comprising ₹1.46 crore tax, ₹0.90 crore interest, and ₹0.15 crore penalty. The company maintains its dialysis services are GST-exempt and contests the demand's validity while facing parallel recovery proceedings.
16Mar 26
Nephrocare Health Services Limited schedules investor conference for March 23, 2026 at Dam Capital Conference
Nephrocare Health Services Limited has announced its participation in Dam Capital Conference scheduled for March 23, 2026 in Mumbai, starting at 10:00 A.M. IST. The company notified BSE and NSE under SEBI Listing Regulations about the investor meetings, which will include both group and one-on-one sessions with analysts and institutional investors. Company officials confirmed that discussions will be based solely on publicly available information with no unpublished price sensitive information to be shared.
16Mar 26
InCred Securities Initiates Add Rating on Nephrocare Health Services with ₹613 Target Price
InCred Securities has initiated coverage on Nephrocare Health Services with an Add rating and ₹613 target price. The brokerage highlighted the company's market leadership in the growing dialysis segment, strong operational performance, and scalable asset-light tie-up model that supports margins. While acknowledging execution risks, InCred remains positive on the company's growth potential in the expanding dialysis industry.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare TechnologiesNephrocare Health Services
Krsnaa Diagnostics
Suraksha Diagnostic
3B BlackBio DX
Health X Platform
One Global Service Provider
1,607.40
(-0.61%)
1,308.50
(+3.73%)
555.35
(+3.58%)
506.30
(-1.14%)
598.70
(-1.06%)
549.45
(+2.04%)
285.80
(-1.31%)
1,241.20
(+1.60%)
307.25
(-1.40%)
445.35
(+5.00%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
